Kwality Pharmaceuticals Limited has announced the successful registration of Cyclophosphamide 1 Gm in Mexico. This achievement marks a significant milestone in the company's expansion strategy in the Latin American market. Cyclophosphamide, an important chemotherapy medication, is used to treat various types of cancer and some autoimmune disorders. The registration in Mexico aligns with Kwality's focus on developing complex injectable drug products and expanding its global footprint. This move is expected to strengthen the company's position in the oncology segment and contribute to its growth in regulated markets.
Source: BSE India and Kwality Pharmaceuticals Limited corporate announcement